title: Hypotony in patients with uveitis: The Multicenter Uveitis Steroid Treatment (MUST) Trial.
abstract: OBJECTIVE
  To assess the prevalence of hypotony in patients with severe forms of uveitis.
  
  
  METHODS
  The Multicenter Uveitis Steroid Treatment (MUST) Trial, a randomized study, enrolled 255 patients. Patients with hypotony at the baseline visit were identified.
  
  
  RESULTS
  Twenty (8.3%) of 240 patients with sufficient data had hypotony. Hypotony was more common in patients with uveitis ≥5 years duration (odds ratio [OR] = 5.0; p < .01), and in eyes with a history of ocular surgery (vitrectomy vs. none, OR = 3.1; p = .03). Hypotony was less in patients with older age of uveitis onset (>51 years vs. <51 years, OR = 0.1; p = .02), in Caucasian patients (OR = 0.1; p < .01) compared to African American patients. Hypotonous eyes were more likely to have visual impairment (OR = 22.9; p < .01).
  
  
  CONCLUSIONS
  Hypotony is an important complication of uveitis and more commonly affects African-American patients, those with uveitis onset at a younger age, and those with longer disease duration. It is associated with visual impairment.
authors.affiliation: National Eye Institute, National Institutes of Health, Bethesda, Maryland 20892, USA. senh@nei.nih.gov
authors.forename: H Nida
authors.initials: HN
authors.lastname: Sen
authors.forename: Lea T
authors.initials: LT
authors.lastname: Drye
authors.forename: Debra A
authors.initials: DA
authors.lastname: Goldstein
authors.forename: Theresa A
authors.initials: TA
authors.lastname: Larson
authors.forename: Pauline T
authors.initials: PT
authors.lastname: Merrill
authors.forename: Peter R
authors.initials: PR
authors.lastname: Pavan
authors.forename: John D
authors.initials: JD
authors.lastname: Sheppard
authors.forename: Alyce
authors.initials: A
authors.lastname: Burke
authors.forename: Sunil K
authors.initials: SK
authors.lastname: Srivastava
authors.forename: Douglas A
authors.initials: DA
authors.lastname: Jabs
mesh_terms: D000293:Adolescent; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use*; D000328:Adult; D000818:Animals; D044383:Black People / Q000706:statistics & numerical data; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015814:Ocular Hypotension / Q000188:drug therapy / Q000453:epidemiology / Q000208:ethnology / Q000209:etiology*; D015995:Prevalence; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014605:Uveitis / Q000150:complications* / Q000188:drug therapy / Q000453:epidemiology / Q000208:ethnology; D014792:Visual Acuity / Q000187:drug effects; D044465:White People / Q000706:statistics & numerical data; D055815:Young Adult; D001741:Black or African American
chemical_list: D000305:Adrenal Cortex Hormones